Review Article
Metastatic Squamous Cell Carcinoma of the Anus: Time for a Shift in the Treatment Paradigm?
Table 3
Studies of cetuximab in metastatic anal squamous cell carcinoma.
| | Author | Number of patients | Agent | Response | PFS/duration of response | OS |
| | De Dosso et al. [29] | 1 | Irinotecan + cetuximab | Partial | Patient died of PE on treatment | NR | | Lukan et al. [30] | 7 | Irinotecan + cetuximab | 5/7 response* (3 partial, 1 minor, and 1 stable) | 6 | NR | | Phan and Hoff [31] | 1 | Irinotecan + cetuximab | Partial | NR | NR |
|
|
* All five that responded were KRAS wild type.
|
